NCT01356290

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2014-04Est. Completion: 2030-04

Enrollment target: 232 participants

Locations

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, United States
Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
Dell Children's Medical Group SFC-HEM/ONC, Austin, Texas, United States
Medical University of Graz, Graz, Austria
Medical University of Innsbruck, Innsbruck, Austria
Kepler Universitätsklinikum Med Campus IV, Linz, Austria
Salzburger Universitätsklinikum, Salzburg, Austria
Medical University of Vienna, Vienna, Austria
University Hospital Brno, Brno, Czechia
Motol University Hospital Prague, Prague, Czechia
University hospital Rigshospitalet, Copenhagen, Denmark
Centre Oscar Lambret, Lille, France
Centre Léon Bérard, Lyon, France
Onkologisk-hematologisk seksjon Barneklinikken Haukeland universitetssjukehus, Bergen, Bergen, Norway
Hospital Infantil Universitario Nino Jesus, Madrid, Spain
Sahlgrenska Universitetssjukhuset, Gothenburg, Sweden

Brain Tumor

Dissemination of medulloblastoma is an independent risk factor of poor prognosis. Dissemination of medulloblastoma at re…

St Louis, United StatesEst. completion Apr 30, 2028

Diffuse Midline GliomaDiffuse Midline High-grade GliomaMedulloblastomaEpendymoma

This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG)…

St Louis, United StatesCompleted Aug 31, 2031

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.